Amylyx Pharmaceuticals
AMLX
26.02
-0.18
-0.69%
Amylyx Pharmaceuticals
US · AMLX
#2392 by market cap
Listed 2022
26.02
-0.18
-0.69%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
C+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 9 analysts
Buy
Avg price target 46.25 +77.7%
Price target rangecurrent 26.02
Low39.00
Avg46.25
High57.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-10 | Mizuho Securities | -- | Buy | 39.00 |
| 2026-11-05 | Citi | -- | Buy | 39.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 38.00 |
| 2026-10-16 | Citi | -- | Buy | 39.00 |
| 2026-10-15 | Citi | -- | Buy | 39.00 |
| 2026-10-01 | Stifel | -- | Buy | 45.00 |
| 2026-08-26 | Guggenheim | -- | Buy | 57.00 |
| 2026-08-22 | LifeSci Capital | -- | Buy | 44.00 |
| 2026-08-20 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-08-19 | Mizuho Securities | -- | Buy | 42.00 |
| 2026-08-19 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-08-18 | TD Cowen | -- | Buy | -- |
| 2026-08-18 | LifeSci Capital | -- | Buy | 44.00 |
| 2026-08-18 | Mizuho Securities | -- | Buy | 42.00 |
| 2026-08-18 | BofA Securities | -- | Buy | 39.00 |
| 2026-08-18 | Baird | -- | Buy | 52.00 |
| 2026-08-18 | Stifel | -- | Buy | -- |
| 2026-08-18 | Citi | -- | Buy | 32.00 |
| 2026-08-18 | Guggenheim | -- | Buy | 55.00 |
| 2026-08-18 | H.C. Wainwright | -- | Buy | 55.00 |
| 2026-08-17 | Mizuho Securities | -- | Buy | 30.00 |
| 2026-08-07 | Baird | -- | Buy | 28.00 |
| 2026-08-07 | H.C. Wainwright | -- | Buy | 34.00 |
| 2026-08-06 | TD Cowen | -- | Buy | -- |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-05 | -- | ±10.38% | -6.05% (in line) |
| 2026/Q2 | 2026-08-06 | -- | ±29.34% | +10.71% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±9.74% | -5.35% (in line) |
| 2025/Q4 | 2026-03-03 | -- | ±19.28% | -7.78% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±18.20% | -5.89% (in line) |
| 2025/Q2 | 2025-08-07 | -- | ±18.78% | -4.27% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±26.63% | -5.95% (in line) |
| 2024/Q4 | 2025-03-04 | -- | ±21.67% | +0.33% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±17.35% | +5.14% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±24.20% | -4.26% (in line) |
| 2024/Q1 | 2024-05-09 | -- | ±15.03% | -2.07% (in line) |
| 2023/Q4 | 2024-02-22 | -- | ±24.55% | +21.10% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Amylyx Pharmaceuticals discussion 0 comments